IGM Biosciences, Inc.
NASDAQ:IGMS
16.03 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 113.112 | 121.231 | 133.334 | 241.08 | 35.891 | 1.887 | 0.432 |
| Short Term Investments
| 225.157 | 305.931 | 96.208 | 125.189 | 188.743 | 0 | 0 |
| Cash and Short Term Investments
| 338.269 | 427.162 | 229.542 | 366.269 | 236.607 | 1.887 | 0.432 |
| Net Receivables
| 0.8 | 0 | 0 | 0 | 0.035 | 0.035 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | -11.973 | 0 | 0 |
| Other Current Assets
| 8.528 | 10.57 | 10.504 | 7.003 | 6.431 | 0.485 | 0.223 |
| Total Current Assets
| 347.597 | 438.421 | 240.747 | 373.272 | 231.1 | 2.407 | 0.655 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 74.005 | 73.075 | 56.344 | 34.812 | 18.019 | 1.472 | 0.677 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 11.973 | 0.1 | 0.05 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 1.809 | 2.003 | 1.036 | 0.548 | 0.258 | 0 | 0.008 |
| Total Non-Current Assets
| 75.814 | 75.078 | 57.38 | 35.36 | 30.25 | 1.572 | 0.735 |
| Total Assets
| 423.411 | 513.499 | 298.127 | 408.632 | 261.35 | 3.979 | 1.39 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 1.326 | 2.512 | 5.584 | 7.924 | 3.087 | 0.164 | 0.225 |
| Short Term Debt
| 5.834 | 5.816 | 3.32 | 2.667 | 2.483 | 5.027 | -0.116 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0.128 |
| Deferred Revenue
| 3.777 | 148.931 | 0 | 0 | 0 | 3.69 | 0.116 |
| Other Current Liabilities
| 31.544 | -112.574 | 18.876 | 6.649 | 3.305 | 0.009 | 0.751 |
| Total Current Liabilities
| 42.481 | 44.685 | 27.78 | 17.24 | 8.875 | 8.89 | 0.976 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 34.672 | 35.356 | 25.439 | 9.577 | 12.244 | 0 | 0 |
| Deferred Revenue Non-Current
| 143.024 | 146.195 | 0 | 0 | 0 | 0 | 0.125 |
| Deferred Tax Liabilities Non-Current
| -143.024 | -146.195 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 143.024 | 146.195 | 0 | 0 | 0 | 60.917 | 40.792 |
| Total Non-Current Liabilities
| 177.696 | 181.551 | 25.439 | 9.577 | 12.244 | 60.917 | 40.917 |
| Total Liabilities
| 220.177 | 226.236 | 53.219 | 26.817 | 21.119 | 69.807 | 41.893 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 261.35 | 60.917 | 40.783 |
| Common Stock
| 0.586 | 0.431 | 0.325 | 0.319 | 0.304 | 0.004 | 0.004 |
| Retained Earnings
| -821.242 | -574.826 | -353.724 | -188.56 | -107.205 | -64.072 | -41.361 |
| Accumulated Other Comprehensive Income/Loss
| 0.151 | -0.701 | -0.066 | 0.026 | 0.043 | -0.667 | -0.389 |
| Other Total Stockholders Equity
| 1,023.739 | 0.27 | -0.259 | -0.345 | -261.697 | -62.01 | -39.54 |
| Total Shareholders Equity
| 203.234 | -574.826 | -353.724 | -188.56 | -107.205 | -65.828 | -40.503 |
| Total Equity
| 203.234 | -574.826 | -353.724 | -188.56 | -107.205 | -65.828 | -40.503 |
| Total Liabilities & Shareholders Equity
| 423.411 | -348.59 | -300.505 | -161.743 | -86.086 | 3.979 | 1.39 |